Study Summary
This trial is testing the long-term safety of a drug called CAM2029 in patients with a condition called acromegaly. Patients will get the drug once a month for 12 months, and then may be able to keep getting it for another year.
Treatment Effectiveness
Effectiveness Progress
Study Objectives
1 Primary · 4 Secondary · Reporting Duration: Week 50 to 52
Trial Safety
Safety Progress
Trial Design
1 Treatment Group
CAM2029 (octreotide subcutaneous depot)
1 of 1
Experimental Treatment
140 Total Participants · 1 Treatment Group
Primary Treatment: CAM2029 (octreotide subcutaneous depot) · No Placebo Group · Phase 3
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18+ · All Participants · 7 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Frequently Asked Questions
Are there any other ongoing or completed research studies that have used CAM2029 (octreotide subcutaneous depot)?
"CAM2029 (octreotide subcutaneous depot) was first studied in 1997 at Vanderbilt University Autonomic Dysfunction Center. Since the initial study, 105 more have been completed with 16 presently active and recruiting patients. The majority of these studies are based out of Missouri's largest city, Saint Louis." - Anonymous Online Contributor
For what purpose is CAM2029 (octreotide subcutaneous depot) most often prescribed?
"octreotide is frequently treated with CAM2029 (octreotide subcutaneous depot). Other conditions that this medication can help manage include long-term maintenance therapy, acromegaly, and metastatic carcinoid tumors." - Anonymous Online Contributor
At how many different test sites is this research being conducted?
"There are 11 sites enrolling patients for this clinical trial, which include locations such as Saint Louis, Los Angeles and Cincinnati. To reduce the burden of travel on participants, it is best to select a location closest to you." - Anonymous Online Contributor
Has CAM2029 (octreotide subcutaneous depot) received FDA approval?
"CAM2029 (octreotide subcutaneous depot) has been given a safety rating of 3. This is based on the fact that it is currently in Phase 3 clinical trials, meaning that there is both evidence of efficacy and multiple rounds data supporting its safety." - Anonymous Online Contributor
Does this experiment still need more test subjects?
"This information can be found on clinicaltrials.gov; the study is still recruiting patients and was first posted on 10/10/2019 with a most recent edit on 9/1/2022." - Anonymous Online Contributor